tiprankstipranks
In this article:
Blurbs

United Therapeutics (UTHR) Gets a Buy Rating from J.P. Morgan

In this article:
In this article:

In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on United Therapeutics (UTHRResearch Report), with a price target of $245.00. The company’s shares closed last Thursday at $203.75.

According to TipRanks.com, Fye is a 4-star analyst with an average return of 11.3% and a 53.6% success rate. Fye covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, Intra-Cellular Therapies, and Mersana Therapeutics.

Currently, the analyst consensus on United Therapeutics is a Moderate Buy with an average price target of $255.00.

See the top stocks recommended by analysts >>

United Therapeutics’ market cap is currently $9.18B and has a P/E ratio of 20.65.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Read More on UTHR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed